• CaMaRa launched with seed financing backed by Forbion Capital Partners Management Services BV as part of a VC syndicate.
• The startup uses human genetics and an AI-driven target assessment framework to identify drug targets in cardiometabolic, renal diseases.
• Strategy pairs target discovery with in-licensing clinic-ready assets to accelerate clinical proof-of-concept in high-value indications.
• CaMaRa also formed a scientific collaboration with the Broad Institute to link genetic variants to disease biology.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Forbion Capital Partners Management Services BV published the original content used to generate this news brief on September 09, 2026, and is solely responsible for the information contained therein.